Prostate Cancer Update, Issue 2, 2021 — Part 1: Our interview with Dr Ryan highlights the following topics as well as cases from his practice:

• Practical factors influencing the selection of therapy for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) (0:00)
• Case: A man in his late 60s with nmCRPC receives first-line therapy with abiraterone (29:53)
• Case: A man with CRPC and high microsatellite instability attains a dramatic response to pembrolizumab (37:31)
• Perspective on the use of adjuvant radiation and salvage radiation therapy for patients with prostate cancer (46:10)
• PSMA (prostate-specific membrane antigen)-targeted PET scanning in prostate cancer; therapeutic approach to M0 disease in patients who experience disease progression on androgen deprivation therapy (48:49)
• Benefits of early initiation of secondary hormonal therapy (57:06)
• Counseling patients about therapeutic options for mHSPC; considerations for clinical care in the COVID-19 era (1:01:08)
• Choice of secondary hormonal therapy for patients with metastatic prostate cancer (1:09:21)
• Selection and sequencing of therapy for patients with mCRPC (1:12:03)
• Management of disease that progresses on androgen receptor (AR)-targeted therapy; CARD trial of cabazitaxel versus AR-targeted agents for patients with previously treated mCRPC (1:16:34)
• Role of chemotherapy and PARP inhibitors for patients with prostate cancer and DNA damage repair gene alterations (1:20:02)

CME information and select publications

Prostate Cancer Update, Issue 2, 2021 — Part 2: Our most recent one-on-one interview with Professor de Bono featuring emerging research and cases from his practice:

• Current and future management of metastatic castration-resistant prostate cancer (mCRPC); role of PARP inhibition as a therapeutic strategy (0:00)
• Choice of therapy for patients with mCRPC who experience disease progression on second-generation antiandrogen agents (24:25)
• Biology of prostate cancer and spectrum of genetic alterations (28:48)
• Therapeutic approach to mCRPC with a BRCA2 mutation (33:00)
• Genomic testing for patients with prostate cancer (41:33)
• Role of ATM mutations in prostate cancer; prevalence of homologous recombination deficiency-related signatures and implications for therapeutic decision-making (45:05)
• Monitoring and managing side effects associated with PARP inhibitors (51:40)
• Management of CRPC in patients who experience disease progression on secondary hormonal therapy (57:47)
• Design and results from the Phase III PROfound study comparing olaparib to AR-targeted therapy for patients with mCRPC harboring homologous recombination repair gene alterations (1:03:34)
• Efficacy of olaparib in Cohort B (patients with mCRPC with homologous recombination repair gene alterations other than BRCA1/2 or ATM) of the PROfound study (1:07:42)
• Activity of rucaparib monotherapy in patients with mCRPC (1:18:00)
• Results of the Phase III HERO trial evaluating relugolix, an oral GnRH receptor antagonist, versus leuprolide for advanced prostate cancer (1:25:32)

CME information and select publications

Featuring an interview with Dr Gilles Salles on the following topics:

• Novel and emerging strategies for diffuse large B-cell lymphoma (DLBCL) (0:00)
• Available efficacy and safety data with the antibody-drug conjugate polatuzumab vedotin for DLBCL (1:01)
• Mechanism of action of selinexor, the novel selective inhibitor of nuclear export; key efficacy and safety findings from the pivotal Phase II SADAL trial of selinexor for relapsed/refractory (R/R) DLBCL (8:15)
• Emerging data with tafasitamab and biologic rationale for combining it with lenalidomide for DLBCL; benefits and risks of tafasitamab/lenalidomide for patients with R/R DLBCL (14:58)
• Role of chimeric antigen receptor (CAR) T-cell therapies in the management of DLBCL (25:18)
• Therapeutic algorithm for patients with DLBCL (31:35)
• Biologic rationale for the investigation of the novel bispecific antibody mosunetuzumab; activity and tolerability of mosunetuzumab in DLBCL (38:46)
• Efficacy of the antibody-drug conjugate loncastuximab tesirine and the anti-CD47 antibody magrolimab; role of venetoclax-based therapy for DLBCL (45:34)
• Case: A man in his late 60s with DLBCL receives polatuzumab vedotin in combination with bendamustine/rituximab (B/R) after disease progression on 3 lines of therapy, including autologous stem cell transplant and CAR T-cell therapy (53:30)
• Sequencing of tafasitamab/lenalidomide, polatuzumab vedotin/BR and selinexor for patients with R/R DLBCL (1:01:32)
• Response to bispecific antibodies in patients with DLBCL (1:04:59)
• Case: A woman in her mid-70s receives tafasitamab and lenalidomide after experiencing disease relapse on R-CHOP for Stage IV DLBCL (1:09:22)
• Case: A man in his early 70s presents with DLBCL with C-MYC and Bcl-2 translocation (1:11:21)

CME information and select publications

Featuring slide presentations and related discussion from Drs Matthew Gubens and Suresh S Ramalingam, including the following topics:

• Nontargeted Therapies for Metastatic Non-Small Cell Lung Cancer — Matthew Gubens, MD, MS (0:00)
• Small Cell Lung Cancer and Mesothelioma — Suresh S Ramalingam, MD (35:33)

CME information and select publications

Featuring perspectives from Drs Matthew Gubens and Suresh S Ramalingam, including the following topics:

• Introduction (0:00)
• Non-Small Cell Lung Cancer (7:55)
• Malignant Pleural Mesothelioma (34:03)
• Small Cell Lung Cancer (43:30)

CME information and select publications

Featuring an interview with Dr Andrew H Wei on the following topics:

• Treatment of acute myeloid leukemia (AML) in patients not eligible for intensive induction therapy (0:00)
• Case: A man in his late 70s with AML receives re-treatment with venetoclax and azacitidine after attaining a durable remission of 2.5 years with that regimen (21:23)
• Case: A woman in her late 70s initially diagnosed with AML with an IDH2 mutation receives gilteritinib as third-line therapy after detection of a FLT3-ITD mutation (23:16)

CME information and select publications

Featuring an interview with Dr Antonio González-Martín. CME information and select publications

Featuring slide presentations and related discussion from Drs Christopher R Flowers and Sonali M Smith on the following topics:

• Follicular Lymphoma (FL) and Mantle-Cell Lymphoma (MCL) — Christopher R Flowers, MD, MS (0:00)
• Diffuse Large B-cell Lymphoma and Hodgkin Lymphoma — Sonali M Smith, MD (40:22)

CME information and select publications

Proceedings from a webinar featuring key clinical presentations and papers in lymphomas. Featuring perspectives from Drs Christopher R Flowers and Sonali M Smith on the following topics:

• Introduction (0:00)
• Follicular lymphoma (2:24)
• Mantle cell lymphoma (15:01)
• Diffuse large B-cell lymphoma (23:48)
• Hodgkin lymphoma (39:37)
• CAR T-cell therapy (50:13)

CME information and select publications

Featuring an interview with Prof Solange Peters on the following topics:

• Emerging biomarkers for predicting response to cancer immunotherapy (0:00)
• Case: A man in his late 50s with metastatic pleomorphic carcinoma of the lung and a high tumor mutational burden (TMB) attains a complete response to pembrolizumab (25:43)
• Role of TMB in determining response to immune checkpoint inhibitors; FDA approval of pembrolizumab for TMB-high (≥10 mut/Mb) solid tumors and implications for clinical practice (29:48)
• Assessment of TMB as a biomarker for use of immunotherapy; variation of TMB over time (34:40)
• Correlation between TMB or PD-L1 level and smoking status; role of POLE mutations and the STING pathway in the immune response (38:51)
• Rationale for the investigation of PARP inhibitors in combination with immunotherapy (43:04)
• Efficacy of cemiplimab versus chemotherapy for PD-L1-high advanced non-small cell lung cancer (NSCLC) (47:25)
• Diversity of the gut microbiome as a potential predictor of response to immune checkpoint inhibitors (49:42)
• Effect of PD-1/PD-L1 expression on the immune response; assays for the assessment of PD-L1 status (55:05)
• Activity of the anti-TIGIT antibody tiragolumab in combination with atezolizumab for PD-L1-high advanced NSCLC; potential role of neoantigen burden as a predictor of response to immunotherapy (59:04)
• Consideration of the benefits and risks of immunotherapy for cancer (1:08:24)

CME information and select publications